- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06666491
Interventiotutkimus tafenokiinin (TQ) ja primakiinin (PQ) tehon ja turvallisuuden vertaamiseksi, kun kumpaakin käytetään yhdessä klorokiinin (CQ) kanssa P. Vivax -malarian hoitoon 2-vuotiailla ja sitä vanhemmilla intialaisilla osallistujilla
Satunnaistettu, avoin, monikeskus, interventiovaiheen 3 tutkimus tehosta ja. Tafenokiinin turvallisuus verrattuna primakiiniin (molemmat annettuna yhdessä klorokiinin kanssa) Plasmodium Vivax (P. Vivax) -malarian radikaaliseen parantamiseen (relapsien ehkäisyyn) intialaisilla osallistujilla (lapsi- ja aikuisväestö)
The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: US GSK Clinical Trials Call Center
- Puhelinnumero: 877-379-3718
- Sähköposti: GSKClinicalSupportHD@gsk.com
Tutki yhteystietojen varmuuskopiointi
- Nimi: EU GSK Clinical Trials Call Center
- Puhelinnumero: +44 (0) 20 89904466
- Sähköposti: GSKClinicalSupportHD@gsk.com
Opiskelupaikat
-
-
-
Ahmedabad, Intia, 380008
- Rekrytointi
- GSK Investigational Site
-
Ottaa yhteyttä:
- US GSK Clinical Trials Call Center
- Puhelinnumero: 877-379-3718
- Sähköposti: GSKClinicalSupportHD@gsk.com
-
Ottaa yhteyttä:
- EU GSK Clinical Trials Call Centre
- Puhelinnumero: +44 (0) 20 8990 4466
- Sähköposti: GSKClinicalSupportHD@gsk.com
-
Päätutkija:
- Leena Dabhi
-
Bikaner, Intia, 334001
- Rekrytointi
- GSK Investigational Site
-
Ottaa yhteyttä:
- US GSK Clinical Trials Call Center
- Puhelinnumero: 877-379-3718
- Sähköposti: GSKClinicalSupportHD@gsk.com
-
Ottaa yhteyttä:
- EU GSK Clinical Trials Call Centre
- Puhelinnumero: +44 (0) 20 8990 4466
- Sähköposti: GSKClinicalSupportHD@gsk.com
-
Päätutkija:
- Sanjay Kumar Kochar
-
Kolkata, Intia, 700073
- Rekrytointi
- GSK Investigational Site
-
Ottaa yhteyttä:
- US GSK Clinical Trials Call Center
- Puhelinnumero: 877-379-3718
- Sähköposti: GSKClinicalSupportHD@gsk.com
-
Ottaa yhteyttä:
- EU GSK Clinical Trials Call Centre
- Puhelinnumero: +44 (0) 20 8990 4466
- Sähköposti: GSKClinicalSupportHD@gsk.com
-
Päätutkija:
- Arunansu Talukdar
-
Mumbai, Intia, 400012
- Rekrytointi
- GSK Investigational Site
-
Ottaa yhteyttä:
- US GSK Clinical Trials Call Center
- Puhelinnumero: 877-379-3718
- Sähköposti: GSKClinicalSupportHD@gsk.com
-
Ottaa yhteyttä:
- EU GSK Clinical Trials Call Centre
- Puhelinnumero: +44 (0) 20 8990 4466
- Sähköposti: GSKClinicalSupportHD@gsk.com
-
Päätutkija:
- Nithya Gogtay
-
Surat, Intia, 395004
- Rekrytointi
- GSK Investigational Site
-
Ottaa yhteyttä:
- US GSK Clinical Trials Call Center
- Puhelinnumero: 877-379-3718
- Sähköposti: GSKClinicalSupportHD@gsk.com
-
Ottaa yhteyttä:
- EU GSK Clinical Trials Call Centre
- Puhelinnumero: +44 (0) 20 8990 4466
- Sähköposti: GSKClinicalSupportHD@gsk.com
-
Päätutkija:
- Shailesh Jethwa
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Males and females >=2 years of age and under (<) 65 years of age, weighing >10 kg.
-
The participant has a positive malarial smear for P. vivax with a parasite density of >100/microliter and <100,000/microliter.
-
The participant has a screening Hb value >8 g/dL.
-
The participant has an axillary temperature of 37.5°C or history of fever 48 hours before recruitment.
-
The participant has a G6PD value (measured using the SD Biosensor STANDARDTM G6PD test) 6.1 units/gram (U/g) Hb for G6PD activity (6.1 U/g Hb cut-off is applicable for both males and females).
-
A female participant is eligible to participate if she is not pregnant or breastfeeding, and if one of the following conditions applies:
- Is a woman of non-childbearing potential (WONCBP) as defined in
- Is a Women of Childbearing Potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, during the study intervention period and for at least 90 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
-
A WOCBP must test negative on a highly sensitive pregnancy test (urine or serum as required by local regulations) before the first dose of study intervention.
-
The participant is willing and able to comply with the procedures described in the study protocol. The participant or parent/legal guardian, as applicable, has given written informed, dated consent; and the participant has given written assent, if applicable, to participate in the study.
Exclusion Criteria:
-
The participant has severe P. vivax malaria as defined by WHO criteria [WHO, 2023].
-
The participant has a mixed malaria infection (identified by a malarial smear).
-
The participant has a condition that may affect absorption of study medication, such as severe vomiting (no food or inability to take food during the previous 8 hours).
-
The participant has a history of porphyria, psoriasis, or epilepsy.
-
The participant has a history of allergy, intolerance to or a known contraindication to the use of mefloquine (or other aryl amino alcohol drugs), chloroquine, tafenoquine, primaquine, any other 4- or 8-AQ or any of their respective excipients.
-
The participant has received treatment with any investigational drug within 30 days of study entry, or within 5 half-lives, whichever is longer.
-
The participant has previously enrolled in this study.
-
The participant has a recent history of illicit drug abuse or heavy alcohol intake that in the opinion of the investigator could compromise full participation in the study or adherence to study procedures.
-
Participants with a current or past history of serious psychiatric disorders.
-
The participant has a clinically significant concurrent illness (e.g., pneumonia, tuberculosis, meningitis, septicemia, dengue, coagulopathy, severe hemorrhage, or febrile convulsions prior to consent) or a pre-existing condition (e.g., renal disease, malignancy, or severe malnutrition according to WHO child growth standards) or systemic disease predisposing patients to suffer from granulocytopenia, such as rheumatoid arthritis and lupus erythematosus or severe ocular disease.
-
The participant is known to be HIV-infected and/or is currently on antiretroviral therapy.
-
The participant is regularly using drugs with hemolytic potential.
-
The participant has a QT corrected by Fridericia's formula (QTcF) >450 msec, evidence of bradycardia (<50 beats per min) or ventricular arrhythmias on the screening ECG, a history of cardiac disease (e.g., myocardial infarction, congenital heart disease, or arrhythmia), hypokalemia (<2.9 millimoles per liter [mmol/L]) or hyperkalemia (>=6.0 mmol/L) at Screening.
-
The participant has taken drugs with antimalarial activity (e.g., artemisinin-based combination therapies, mefloquine, primaquine, chloroquine, tafenoquine or any other 4-AQ) within 30 days prior to study entry.
-
The participant has taken or will likely require during the study the use of:
- Histamine-2 blockers (restricted to first 3 days whilst receiving CQ)
- Antacids (restricted to first 3 days whilst receiving CQ)
- Drugs of the biguanide class (i.e., phenformin, metformin, buformin)
- Anti-arrhythmic agents (i.e., dofetilide, procainamide, pilsicainide)
- Medications that prolong the QTc interval
-
The participant has liver transaminases (ALT/AST) >2 times the upper limit of normal (ULN).
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: TQ/CQ
Participants in this group receive a single dose of TQ on Day 1 or Day 2 and a single dose of CQ daily, on Days 1 to 3. |
A single dose of TQ will be administered orally on Day 1 or Day 2. A single dose of CQ will be administered orally, daily, on Days 1 to 3. |
|
Active Comparator: PQ/CQ
Participants in this group receive a single dose of PQ daily from Day 1 or 2, up to Day 14 (or Day 15 if PQ started on Day 2) and a single dose of CQ daily, on Days 1 to 3. |
A single dose of CQ will be administered orally, daily, on Days 1 to 3. A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2). |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of participants remaining recurrence-free during the 6 months post-treatment and have a negative blood smear at the Month 6 (end of study [EOS]) visit
Aikaikkuna: Up to Month 6
|
Two consecutive negative blood smears between Day 2 and Day 8, no positive blood smear for P. vivax parasites at any point during the 6-month follow-up period, and a negative P. vivax smear at the 6-month assessment. |
Up to Month 6
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Kuolemien määrä
Aikaikkuna: 6 kuukauteen asti
|
6 kuukauteen asti
|
|
|
Laboratorioparametrit täyttävät >= AIDS-jako (DAID) Grade 3 kriteerit
Aikaikkuna: 6 kuukauteen asti
|
6 kuukauteen asti
|
|
|
Vital sign parametrit täyttävät >=DAIDs Grade 3 kriteerit
Aikaikkuna: 6 kuukauteen asti
|
6 kuukauteen asti
|
|
|
Muutos lähtötasosta kullakin tutkimuskäynnillä hematologisten parametrien osalta (retikulosyyttien prosenttiosuus)
Aikaikkuna: Päivinä 5, 8, 15, 29, 60, 90, 120, 150 ja 180
|
Päivinä 5, 8, 15, 29, 60, 90, 120, 150 ja 180
|
|
|
Number of participants with clinically relevant hemolysis change from baseline
Aikaikkuna: Up to Day 14
|
A decrease in hemoglobin of greater than or equal to (>=) 30% or greater than (>) 3g/deciliter (dL) from baseline; or an overall drop in hemoglobin below 6.0 g/dL or complications thereof (e.g., required transfusions, acute renal failure) are considered clinically relevant hemolysis changes. |
Up to Day 14
|
|
Time to recurrence of P. vivax malaria
Aikaikkuna: Up to Month 6
|
Recurrence is defined as a positive blood smear for P. vivax parasites within the 6-month follow-up period, after clearance of blood-stage parasitemia. |
Up to Month 6
|
|
Number of participants with treatment emergent adverse events (TEAEs) up to Month 6
Aikaikkuna: Up to Month 6
|
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Number of participants with TEAEs meeting >= Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 criteria
Aikaikkuna: Up to Month 6
|
Severity was graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening, Grade 5-Death. |
Up to Month 6
|
|
Number of participants with drug related TEAEs
Aikaikkuna: Up to Month 6
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Number of participants with serious AEs (SAEs)
Aikaikkuna: Up to Month 6
|
A SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization or result in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant. |
Up to Month 6
|
|
Number of participants with AEs resulting in treatment discontinuation
Aikaikkuna: Up to Month 6
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Number of participants with AEs leading to study withdrawal
Aikaikkuna: Up to Month 6
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Number of participants with AEs considered to be hematologically related
Aikaikkuna: Up to Month 6
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Liver chemistry changes meeting Hy's criteria
Aikaikkuna: Up to Month 6
|
Hy's criteria cases were defined as any elevated alanine aminotransferase (ALT) >=3 times upper limit of normal (ULN) and total bilirubin >=2 times ULN or ALT >=3 times ULN and international normalized ratio (INR) >1.5. |
Up to Month 6
|
|
Number of participants with TEAEs up to Week 4
Aikaikkuna: Up to Week 4
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Week 4
|
|
Change from baseline at each study visit for clinical chemistry parameters (ALT, AST, ALP)
Aikaikkuna: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) is measured in international units/liter (IU/L). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for clinical chemistry parameters (CPK)
Aikaikkuna: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for creatine phosphokinase (CPK) is measured in units per liter (U/L). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for clinical chemistry parameters (total bilirubin, indirect bilirubin, blood urea nitrogen [BUN]/Urea, and serum creatinine)
Aikaikkuna: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Clinical chemistry parameters are measured in milligrams per decilitre (mg/dL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for clinical chemistry parameters (serum electrolytes)
Aikaikkuna: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for serum electrolytes is measured in millimoles per liter (mmol/L). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (platelet count)
Aikaikkuna: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Platelets are measured in number of platelets per microliter (µL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (red blood cell [RBC] count)
Aikaikkuna: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for RBC is measured in millions of cells per microliter (number of RBCs x10^6/µL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (mean corpuscular volume [MCV])
Aikaikkuna: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for MVC is measured in femtoliters (fL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (mean corpuscular hemoglobin [MCH])
Aikaikkuna: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for MCH is measured in picograms (pg) per cell. |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (white blood cell count [WBC] with differential)
Aikaikkuna: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for neutrophils, lymphocytes, monocytes, eosinophils and basophils is presented as a count, which measures a percentage (%) of the WBC. |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (hemoglobin)
Aikaikkuna: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Hemoglobin is measured in grams per deciliter (g/dL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (hematocrit)
Aikaikkuna: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Hematocrit is measured in volume percentage (%) of RBC in blood. |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 208550
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
IPD-jaon aikakehys
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD-jaon käyttöoikeuskriteerit
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- ICF
- CSR
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .